海外の治験の状況「前立腺癌」での検索結果
242件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Authorised
- Study on Olaparib Plus Abiraterone as First-line Therapy in Men with Metastatic Castration-resistant Prostate Cancer
- Metastatic castration-resistant prostate cancer br>MedDRA version: 20.0 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: LLT Classification code 10076506 Term: Castration-resistant prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Belgium, Brazil, Canada, Chile, China, Czech Republic, France, Germany, Italy, Japan, Korea, Republic of, Netherlands, Slovakia, Spain, Turkey, United Kingdom, United States
- 2018-08-22
Authorised
- Randomized, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events (MACEs) in Patients with Prostate Cancer and Cardiovascular Disease Receiving Degarelix or Leuprolide
- Advanced Prostate Cancer br>MedDRA version: 20.0 Level: PT Classification code 10071119 Term: Hormone-dependent prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Canada, Czech Republic, Finland, France, Germany, Greece, Poland, Slovakia, South Africa, United Kingdom, United States
- 2018-07-24
Authorised
- Hormone-refractory Prostate cancer first Line Intermittent Taxotere and Estramustine. - ND
- Prostate cancer. br>MedDRA version: 6.1 Level: PT Classification code 10036909
- Italy
- 2007-01-16
Authorised
- Low-risk prostate cancer br>MedDRA version: 12.1 Level: LLT Classification code 10060862 Term: Prostate cancer
- Belgium, Denmark, Finland, France, Germany, Netherlands, Spain, Sweden, United Kingdom
- 2010-08-03
Authorised
- "VASCULAR-TARGETED PHOTODYNAMIC THERAPY USING WST11 IN PATIENTS WITH LOCALISED PROSTATE CANCE"
- The Treatment of prostate cancer. br>MedDRA version: 9.1 Level: LLT Classification code 10060862 Term: Prostate cancer
- France, Netherlands, United Kingdom
- 2008-03-10
Authorised
- A double-blind, dose-response, phase II, multicentre study of radium-223 (Alpharadin TM ) for the palliation of painful bone metastases in hormone refractory prostate cancer patients
- The target population is patients suffering from bone pain due to skeletal metastasis secondary to prostate cancer.
- Sweden, United Kingdom
- 2004-07-12
Authorised
- A MULTICENTER, OPEN-LABEL CONTINUATION TRIAL EVALUATING THE TOLERABILITY AND ACTIVITY OF DEPSIPEPTIDE (FK228) IN PATIENTS THAT HAVE COMPLETED A PRIOR CLINICAL STUDY WITH DEPSIPEPTIDE - Depsipeptide extension study
- Refractory Prostate cancer br>MedDRA version: 5.0 Level: CTEP Classification code 10036920
- United Kingdom
- 2006-02-06
Authorised
- A Study of Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer
- Metastatic Castrate-Resistant Prostate Cancer br>MedDRA version: 20.0 Level: LLT Classification code 10076506 Term: Castration-resistant prostate cancer System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Austria, Belgium, Brazil, Canada, China, Costa Rica, Denmark, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Mexico, Norway, Poland, Portugal, Russian Federation, Slovenia, Spain, Sweden, Taiwan, Thailand, United Kingdom, United States
- 2017-05-04
Authorised
- PATCH Prostate Adenocarcinoma: TransCutaneous Hormones A randomised-controlled trial of transcutaneous oestrogen patches versus LHRH agonists in prostate cancer.
- Newly diagnosed or relapsing patients with locally advanced or metastatic prostate cancer;Therapeutic area: Diseases [C] - Cancer [C04]
- United Kingdom
- 2005-08-16
Authorised
- A study to find out if being treated with docetaxel, prednisone, and custirsen (new experimental study drug ) can increase survival in patients with metastatic, castrate resistant prostate cancer compared to the currently approved treatment with docetaxel and prednisone. The study will also see if custirsen is safe when given with docetaxel and prednisone.
- metastatic castrate resistant prostate cancer br>MedDRA version: 14.1 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 14.1 Level: LLT Classification code 10062904 Term: Hormone-refractory prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Belgium, Canada, France, Germany, Hungary, Israel, Italy, Korea, Republic of, Netherlands, Spain, United Kingdom, United States
- 2010-08-13